SinoMab BioScience's (HKG:3681) phase 1B China clinical trial of its SM17 drug for moderate-to-severe atopic dermatitis reached its primary endpoints, according to a Monday filing with the Hong Kong bourse.
The drug was well-tolerated during the 16-week trial and follow-up period and showed no serious adverse events, the filing said.
SM17 also showed skin healing effects, while lower doses of the drug showed relief from pruritus or itching compared with those treated with a placebo, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。